Correction to “Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone‐Sensitive Prostate Cancer”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPneumocystis jirovecii pneumonia detection and treatment · Otitis Media and Relapsing Polychondritis · Toxoplasma gondii Research Studies
F. Ito, K. Kobayashi, G. Hayashi, S. Kamijo, T. Fujita, “Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone‐Sensitive Prostate Cancer,” Respirology Case Reports 13, no. 12 (2025): e70435, https://doi.org/10.1002/rcr2.70435.
In this published article, the androgen deprivation therapy was incorrectly described as relugolix in the Abstract and the Case Presentation sections.
In the Abstract section, the text “received triplet therapy with relugolix, darolutamide and docetaxel” was incorrect. It should read “received triplet therapy with degarelix, darolutamide and docetaxel”.
In the Case Presentation section, the sentence “He began oral relugolix (ADT), followed by darolutamide and docetaxel” was incorrect. It should read “He began degarelix (ADT), followed by darolutamide and docetaxel”.
We apologise for these errors.